Trial Looks to Double Down on Anti-HER2 in Breast Cancer
Currently enrolling, HER2CLIMB-04 combines two newly approved drugs, Both tucatinib (Tukysa) and trastuzumab deruxtecan (Enhertu) have been shown to be highly efficacious in the pivotal HER2CLIMB and DESTINY-Breast01 trials, respectively.
A new study presented at the recent American Society of Clinical Oncology (ASCO) virtual annual meeting aims to assess if the combination of the agents in patients with HER2-positive locally advanced/metastatic breast cancer can further improve the efficacy seen with either agent alone.
HER2CLIMB-4 was presented by Dr. [Ian E.] Krop here at ASCO 2021. And it’s a really exciting study because it combines two of our newest approved drugs in the HER2 space together into one trial. So obviously I’m talking about tucatinib and trastuzumab deruxtecan here. https://bit.ly/3wqNvAJ